白三烯调节剂相关神经精神事件:系统综述
2008年FDA警告可能影响报告率。由于缺乏随机对照试验和观察性研究,风险未能量化。
要点
- 药物警戒研究提示白三烯调节剂与神经精神事件存在信号,但观察性研究证据有限。
- 2008年FDA警告可能提高神经精神事件的报告率,需考虑报告偏倚。
- 需高质量流行病学研究量化儿童和成人中的风险。
核心结论
- 药物警戒研究检测到白三烯调节剂与神经精神事件的关联信号,但观察性研究证据有限且结论不一致。
- 由于缺乏随机对照试验和充分观察性研究,神经精神事件的风险未能量化。
研究设计与样本
- 纳入标准为调查白三烯调节剂与神经精神事件关联的研究,不限研究设计和语言。
主要发现
- 4项观察性研究未发现白三烯调节剂与神经精神事件存在显著关联。
- 部分研究提示2008年FDA警告可能因意识提高而影响神经精神事件的报告率。
关键数值与推荐
- 主要结局为自杀相关状况,次要结局包括所有其他神经精神事件。
临床怎么用
- 临床应关注白三烯调节剂使用者的神经精神症状,尤其是自杀相关状况。
- 处方时需权衡哮喘/过敏性鼻炎治疗获益与潜在神经精神风险。
局限性
- 缺乏随机对照试验和观察性研究,无法量化神经精神事件风险。
- 药物警戒研究可能存在报告偏倚,受FDA警告等外部因素影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Leukotriene-modifying agents (LTMAs) including montelukast, zafirlukast, and zileuton are approved by the US Food and Drug Administration (FDA) for the treatment of asthma and allergic rhinitis. Various neuropsychiatric events (NEs) have been reported; however, the evidence of the association is conflicting. This systematic review investigates the association between NEs and LTMAs by assessing the relevant published literature. METHODS: PubMed, EMBASE, MEDLINE, and Cochrane Library were searched using keywords. Studies designed to investigate the association were eligible for inclusion without restriction to any study design or language. The primary outcome was defined as suicidal conditions, while secondary outcomes included all other NEs. RESULTS: Thirty-three studies were included for a narrative review. Four observational studies did not find a significant association, while ten pharmacovigilance studies using different global databases detected the signals. Notably, some studies suggest that the FDA warning issued in 2008 might have influenced the reporting rate of NEs as a result of increased awareness. LIMITATIONS: The risk of NEs was not quantified, because of the lack of randomized controlled trials and observational studies investigating the association. CONCLUSION: Many pharmacovigilance studies have been conducted to determine the association between NEs and LTMAs, but there is limited evidence from observational studies. High-quality epidemiological studies should be conducted to evaluate the association and quantify the risk, not only in children, but also in adults.
引用
- Law SWY, Wong AYS, Anand S, et al. Neuropsychiatric Events Associated with Leukotriene-Modifying Agents: A Systematic Review. Drug Saf. 2018. PMID: 29076063. doi:10.1007/s40264-017-0607-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。